Results: Modifying the pH of the empirically used commercial tobramycin ophthalmic solution in donkeys at a pH of 8.26 enhanced the drug's bioavailability. The MIC90 of the most hazardous bacteria isolated from
The ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramicine, obtained from Tobramicine itself or from an ...
The ophthalmic solution comprises (a) the equivalent to 0.001-0.14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceutically acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 % of Tobramycine, obtained from Tobramycine itself or from an isomer ...
DICLOFENAC AND TOBRAMYCIN-BASED OPHTHALMIC SOLUTION AND ITS APPLICATIONSThe ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value of 0.001-0.45 %...
Process for the preparation of an ophthalmic solution based on diclofenac and tobramycinThe ophtalmic solution comprises (a) the equivalent to 0.001-0,14 % of Diclofenac itself or an isomer, or a derivative or one of the pharmaceuticaly acceptable salts thereof; (b) the equivalent to a value...
Evaluation of clinical efficacy and safety of /ophthalmic suspension 0.3%/0.05% compared to ophthalmic solution 1% in the treatment of moderate to severe acute /blepharoconjunctivitis.Pediatrics